Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;5(1):35-38.
doi: 10.1016/j.prnil.2017.01.004. Epub 2017 Feb 7.

Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer

Chaiyut Kongseang  1 , Worapat Attawettayanon  1 , Watid Kanchanawanichkul  1 , Choosak Pripatnanont  1
Affiliations

Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer

Chaiyut Kongseang et al. Prostate Int. 2017 Mar.

Abstract

Background: The purpose of this study was to identify the predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (PC) with or without distant metastasis.

Methods: A retrospective review of PC patients was conducted of the medical records. We enrolled 246 patients who received primary ADT. PC patients treated with ADT for presumed nonlocalized PC were evaluated on the efficacy of ADT using prostate-specific antigen (PSA) time to progression (TTP) and compared factors associated with TTP in patients with distant metastasis and patients without distant metastasis.

Results: A total of 246 patients were treated primarily with ADT. The median follow-up period was 20.2 months. One hundred and ninety-one patients had metastatic disease. The median TTP on ADT for the distant metastasis group was 14.8 months versus 60.1 months in the without distant metastasis group (P < 0.0001). In the univariate analysis only, PSA nadir after ADT was associated with longer TTP (hazard ratio, 10.69; 95% confidence interval, 5.56-20.57). In the multivariate analysis, high grade tumor and PSA nadir were independent factors associated with a shorter TTP.

Conclusion: In this study of hormone-sensitive PC patients treated with ADT for nonlocalized PC, high grade tumor and PSA nadir were predicting factors of this treatment.

Keywords: Advanced prostate cancer; Androgen deprivation therapy; Predictive factor; Time to progression.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Time to progression (TTP) according to the nadir prostate-specific antigen (PSA) and the time to PSA nadir.
See this image and copyright information in PMC

References

    1. Lojanapiwat B. Urologic cancer in Thailand. Jpn J Clin Oncol. 2015;45:1007–1015. - PubMed
    1. Tantiwong A., Soontrapa S., Sujijantrarat P., Vanprapar N., Sawangsak L. The prevalence of prostate cancer screening in Thai elderly. J Med Assoc Thai. 2002;85:502–508. - PubMed
    1. Jaswal J., Crook J. The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer. Curr Urol Rep. 2015;16:1–7. - PubMed
    1. Teoh J.Y.C., Tsu J.H.L., Yuen S.K.K., Chiu P.K., Chan S.Y., Wong K.W. Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy. Asian J Androl. 2016;18:1–5. - PMC - PubMed
    1. Cooperberg M.R., Hinotsu S., Namiki M., Carroll P.R., Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016;117:102–109. - PubMed